SBScott T. Ball

Scott T. Ball

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Scott T. Ball has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Adam Jeffrey Engler

    Chien-Lay Department of Bioengineering, UC San Diego, San Diego, California, USA

    1 shared publication
  • Chanond A. Nasamran

    Center for Computational Biology and Bioinformatics, UC San Diego, La Jolla, CA, USA

    1 shared publication
  • Christopher Liu

    Department of Orthopaedic Surgery, University of California San Diego, San Diego, California

    1 shared publication
  • Cooper B. Ehlers

    Department of Orthopaedic Surgery, University of California San Diego, La Jolla, USA

    1 shared publication
  • Frank E. Chiarappa

    Department of Orthopaedic Surgery, University of California San Diego, San Diego, California

    1 shared publication
  • Garrett K. Berger

    From the Department of Orthopaedic Surgery, University of California San Diego, San Diego, CA (Berger), Department of Orthopaedic Surgery (Garrigues), Rush University Medical Center, Chicago, IL, Department of Orthopaedic Surgery (Chalmers), University of Utah, Salt Lake City, UT, and Department of Orthopaedic Surgery, Southern California Permanente Medical Group, San Diego, CA (Singh)

    1 shared publication

Latest Publications

  • Total femur replacement in revision arthroplasty for non-oncologic patients: a systematic review

    by Christopher M. Liu, Cooper B. Ehlers, Garrett K. Berger, Scott T. Ball, Frank E. Chiarappa

    Purpose Revision total joint arthroplasty cases including those complex enough to require limb-salvage procedures are expected to significantly increase. Total femoral replacements represent a limb-preserving procedure with potential utility for these complicated cases. This review seeks to summarize the outcomes of total femoral replacements when used in the revision arthroplasty setting. Methods A systematic review was performed by searching Embase, Ovid MEDLINE, PubMed, Wiley Cochrane Library: Central Register of Controlled Trials, and Thompson Reuters Web of Science: Citation Index on February 8, 2024 for studies describing any outcomes and complications of total femur replacements performed for revision arthroplasty. Functional outcomes and postoperative complications were subsequently summarized. This study was registered with PROSPERO (CRD42024509031). Risk of bias assessment was performed using the Methodological Index for Nonrandomized Studies. Results Eleven of 4817 initially screened studies were included. Indications for total femur replacement largely consisted of periprosthetic infection, periprosthetic fracture, hardware loosening, or a combination thereof. Articles described variable benefit in function, pain, and ambulatory ability. Patients had improved hip and knee function, reduced pain levels, and preserved independent ambulatory ability, though patients largely still required assistive devices. Benefits were limited by the high risk of postoperative complications, especially infection and dislocation. Conclusion Total femur replacement is an option for limb-salvage surgery in complex revision arthroplasty cases but has high complication rates, particularly infection and dislocation. Advancements aimed at minimizing these complication rates including silver- and iodine-coated implants will be critical in establishing the viability of total femur replacements in this setting.


  • Open Access

    Comparative single-cell transcriptional and proteomic atlas of clinical-grade injectable mesenchymal source tissues

    by Severin Ruoss, Chanond A. Nasamran, Scott T. Ball, Jeffrey L. Chen, Kenneth N. Halter, Kelly A. Bruno, Thomas C. Whisenant, Jesal N. Parekh, Shanelle N. Dorn, Mary C. Esparza, et al.

    Bone marrow aspirate concentrate (BMAC) and adipose-derived stromal vascular fraction (ADSVF) are the most marketed stem cell therapies to treat a variety of conditions in the general population and elite athletes. Both tissues have been used interchangeably clinically even though their detailed composition, heterogeneity, and mechanisms of action have neither been rigorously inventoried nor compared. This lack of information has prevented investigations into ideal dosages and has facilitated anecdata and misinformation. Here, we analyzed single-cell transcriptomes, proteomes, and flow cytometry profiles from paired clinical-grade BMAC and ADSVF. This comparative transcriptional atlas challenges the prevalent notion that there is one therapeutic cell type present in both tissues. We also provide data of surface markers that may enable isolation and investigation of cell (sub)populations. Furthermore, the proteome atlas highlights intertissue and interpatient heterogeneity of injected proteins with potentially regenerative or immunomodulatory capacities. An interactive webtool is available online.